Work

A phase 1, open-label, dose escalation study of the safety and tolerability of T3011 in advanced cutaneous or subcutaneous malignancies.

Year: 2021

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2021.39.15_suppl.2526

Authors: Andrew Mark Haydon, Ganessan Kichenadasse, John M. Kirkwood, Howard E. Kaufman, Elizabeth Iannotti Buchbinder, Vinod Ganju, Minal A. Barve, Haifang Jiang, Huinan Xu, Xusha Zhou, Huan J. Zhu, Dongyao Ni, Jiaxin Niu

Institutions: Alfred Health, University of Pittsburgh, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Massachusetts General Hospital, Dana-Farber Cancer Institute, Mary Crowley Cancer Research Center, Banner MD Anderson Cancer Center

Language: English

Topic: Virus-based gene therapy research

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3169435831

Cites:

Cited by: 6

Related to: 10